Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siFZD2
- Development stage
- Preclinical
- Lead developer
- University of California, Davis
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
siFZD2 is a small interfering RNA (siRNA) designed to target and silence the expression of Frizzled-2 (FZD2), a G protein-coupled receptor that serves as a key mediator of non-canonical Wnt5a signaling. In advanced prostate cancer, particularly enzalutamide-resistant castration-resistant prostate cancer (CRPC), the Wnt5a/FZD2 axis is frequently co-upregulated and is associated with tumor progression, neural lineage plasticity, and neuroendocrine differentiation. By knocking down FZD2 expression, siFZD2 inhibits the non-canonical Wnt signaling pathway, suppresses cancer cell proliferation and migration, and resensitizes resistant cells to enzalutamide treatment. Research conducted at the University of California Davis identifies FZD2 as a critical driver of antiandrogen resistance, suggesting that its inhibition could provide therapeutic benefits for patients with advanced prostate cancer expressing high levels of lineage markers.
- Other names
- FZD2 siRNAFZD-2 siRNAFZD 2 siRNAFrizzled-2 siRNAFrizzled2 siRNAFrizzled 2 siRNA
02
Targets
Frizzled class receptor 2 mRNA
Beyond the preview
Go deeper on siFZD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siFZD2.